IRVINE, Calif., July 09, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age, announced today that it will feature its flagship consumer product to help improve the aging process, TRU NIAGEN^®, at the American Association of Naturopathic Physicians Annual Convention as well as the 2018 Healthy Aging Summit.

The sole active ingredient in TRU NIAGEN is nicotinamide riboside, a unique form of vitamin B3 clinically proven to safely increase one’s levels of NAD (nicotinamide adenine dinucleotide). Decreased NAD levels have been associated with many age-related changes in overall health.

The American Association of Naturopathic Physicians Annual Convention will take place in San Diego, CA, from July 12-14—TRU NIAGEN will exhibit at booth #606. AANP is comprised of licensed naturopathic doctors, naturopathic medicine students, and other healthcare professionals to advance the field of naturopathic medicine.

Following the AANP meeting, the TRU NIAGEN team will exhibit at the 2018 Healthy Aging Summit, table #5, in Washington, DC, from July 16-17. Co-hosted by the American College of Preventive Medicine (ACPM) and three government offices, the event is designed to explore the science behind healthy aging by bringing together healthcare practitioners with public health officials, universities, and service providers.

At both events, members of the TRU NIAGEN team will be on site to discuss the scientific evidence behind its revolutionary ingredient, as well as the recently published clinical data supporting its efficacy in humans. Visitors will also receive a complimentary bottle of TRU NIAGEN at the booth—come early as quantities are limited.

For additional information on the science supporting TRU NIAGEN visit www.truniagen.com.

About TRU NIAGEN^®:
TRU NIAGEN^® is a branded dietary supplement brought to market by key nicotinamide riboside innovator and patent holder, ChromaDex. NIAGEN^® nicotinamide riboside (NR), also supplied by ChromaDex, is the sole active ingredient in TRU NIAGEN^®. Multiple clinical trials demonstrate NIAGEN^® is proven to boost NAD (nicotinamide adenine dinucleotide) levels, which decline with age. Only NIAGEN^® has twice been successfully reviewed under FDA's new dietary ingredient (“NDI”) notification program, and has also been successfully notified to the FDA as generally recognized as safe (“GRAS”).

About ChromaDex:
ChromaDex Corp. is an integrated, global nutraceutical company devoted to improving the way people age. ChromaDex scientists partner with leading universities and research institutions worldwide to uncover the full potential of NAD and identify and develop novel, science-based ingredients. Its flagship ingredient, NIAGEN nicotinamide riboside, sold directly to consumers as TRU NIAGEN^®, is backed with clinical and scientific research, as well as extensive IP protection. TRU NIAGEN is helping the world AGE BETTER^®. To learn more about ChromaDex, please visit www.ChromaDex.com.

Forward-Looking Statements:
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, including statements related to results of the NIAGEN^® studies and their significance. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects", "anticipates", "intends", "estimates", "plans", "potential", "possible", "probable", "believes", "seeks", "may", "will", "should", "could" or the negative of such terms or other similar expressions. More detailed information about ChromaDex and the risk factors that may affect the realization of forward-looking statements is set forth in ChromaDex's Annual Report on Form 10-K for the fiscal year ended December 30, 2017, ChromaDex's Quarterly Reports on Form 10-Q and other filings submitted by ChromaDex to the SEC, copies of which may be obtained from the SEC's website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and ChromaDex undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof. ChromaDex provided research materials and a portion of the grant funding as a collaborator for the study.

ChromaDex Media Contact:
Alex Worsham, Director of Strategic Partnerships
949-648-3775
[email protected]

ChromaDex Investor Relations Contact:
Andrew Johnson, Director of Investor Relations
949-419-0288
[email protected]